What one share of Bioatla holds
We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics (“CAB” or “CABs”) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target.
Bioatla’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$22.76 |
|---|---|
| Cash and investments | $0.93 |
| Book value | −$21.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.43 | −$138.02 | — | — | — | $294.45 |
| 2022 | — | −$136.77 | — | — | — | $194.60 |
| 2023 | — | −$129.21 | — | — | — | $73.50 |
| 2024 | — | −$71.83 | — | — | — | $12.28 |
| 2025 | — | −$50.66 | — | — | — | −$28.51 |
Common questions about Bioatla
How much does one share of Bioatla earn?
Over the last 12 months, Bioatla lost $22.76 for each share.
Does Bioatla pay a dividend?
Bioatla didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Bioatla’s book value per share?
Bioatla’s book value is negative (−$21.79 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Bioatla have?
Each share of Bioatla has $0.93 of cash and investments, as of June 30, 2026.
Has Bioatla bought back shares?
Bioatla’s share count rose about 70% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.